Clinical trials: Bone Tumour
Mastocytosis, Monoclonal
Study of Factors Regulating Mast Cell Proliferation
This study will examine growth factors that promote and inhibit mast cell proliferation resulting in mastocytosis, a disease of excessive mast cells in the body.
- Conditions
- Mastocytosis, Monoclonal, Bone Marrow, Tryptase
- Trial name
- NCT00044122
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
This study will assess the efficacy and safety of ibandronate (Bondronat), administered intravenously (IV) or orally (PO), in participants with malignant bone disease and moderate to severe pain.
- Trial name
- NCT02561039
- Testing
- Ibandronate
- Where
- 9 sites in Bulgaria
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Leukemia
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
RATIONALE: Giving chemotherapy drugs, such as cytarabine and mitoxantrone, before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Trial name
- NCT00609739
- Testing
- cyclosporine, cytarabine, filgrastim
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS.
- Trial name
- AML (NCT02576301)
- Testing
- Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Mateon Therapeutics
Osteosarcoma
A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma
Purpose: This study will assess the safety and efficacy of Endostar combined with chemotherapy in osteosarcoma patients.
- Trial name
- NCT01002092
- Testing
- Chemotherapy, Endostar
- Where
- 4 sites in China
- Volunteers
- 160 people
- Sponsor
- Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have…
- Conditions
- Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor
- Trial name
- NCT00019630
- Testing
- doxorubicin HCl liposome
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Refractory Solid Tumors, Ewing Sarcoma
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
- Conditions
- Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma
- Trial name
- NCT02013336
- Testing
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- South Plains Oncology Consortium
Anemia, Leukemia
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
RATIONALE: Thalidomide may stop or slow the growth of cancer cells. Epoetin alfa may stimulate red blood cell production. Combining thalidomide with epoetin alfa may improve anemia, decrease the need for blood transfusions, and…
- Conditions
- Anemia, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00053001
- Testing
- epoetin alfa, thalidomide
- Where
- 2 sites in United States
- Sponsor
- Fallon Clinic
Bone Vascular Tumor
In Vivo Depiction Of Bone Vascularization With UHR-CT CT And Deep Learning Algorithm Reconstruction: A Preliminary Study
To evaluate the image quality and ability to depict in vivo bone vascularization with an ultra-high-resolution computed tomography (UHR-CT) scanner using a deep learning reconstruction (DLR) and hybrid iterative reconstruction…
- Trial name
- NCT05628792
- Testing
- CT
- Volunteers
- 20 people
- Sponsor
- Central Hospital, Nancy, France
Bone Neoplasm of Hip (Diagnosis)
Megaprosthetic Implants the Next Generation (MING)
This is an interventional randomized controlled trial that will compare patients who underwent segmental hip replacement using mega-implants with either porous collar or porous collar with HA.
- Trial name
- MING (NCT03780036)
- Testing
- Megaprosthetic Implants the Next Generation (MING)
- Volunteers
- 30 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00716911
- Testing
- ganciclovir, polymerase chain reaction, flow cytometry
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent
The median age of onset of chronic myeloid leukemia (CML) in chronic phase PC is about 60 years. However CML affects all age groups including 18-25 year olds, called adult-young adolescents (AJA).
- Trial name
- NCT02903277
- Sponsor
- Centre Hospitalier Universitaire de Nice
Breast Cancer, Castration-resistant Prostate Cancer
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA…
- Trial name
- NCT04549207
- Testing
- Bone modifying agent
- Where
- 5 sites in Canada
- Volunteers
- 240 people
- Sponsor
- Ottawa Hospital Research Institute
Metastatic Cancer, Sarcoma
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
RATIONALE: Inhaling aerosolized sargramostim before and after surgery may interfere with the growth of tumor cells and shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00066365
- Testing
- sargramostim, conventional surgery
- Where
- 93 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Children's Oncology Group
Leukemia
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with a TKI that you are already taking (such as Gleevec, Sprycel, or…
- Trial name
- NCT01460498
- Testing
- Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloproliferative Neoplasms
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
- Trial name
- NCT06313593
- Testing
- INCB160058, Standard disease-directed therapy
- Where
- 30 sites in United States, Canada and 6 more
- Volunteers
- 37 people
- Sponsor
- Incyte Corporation
Myelofibrosis, Essential Thrombocythemia
CEP-701 (Lestaurtinib) in Myelofibrosis
Myelofibrosis is the gradual replacement of bone marrow (place where most new blood cells are produced) by fibrous tissue which reduces the body's ability to produce new blood cells and results in the development of chronic…
- Conditions
- Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT00668421
- Testing
- CEP-701 (Lestaurtinib)
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ronald Hoffman
Cancer, Effects of Chemotherapy
Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function
The purpose of this study is to retrieve and cryopreserve ovarian tissue from females undergoing a treatment that may lead to irreversible loss of ovarian function.
- Conditions
- Cancer, Effects of Chemotherapy, Unspecified Complication of Bone Marrow Transplant, Auto Immune Disease
- Trial name
- NCT01993732
- Testing
- Retrieval and Cryopreservation
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Medical College of Wisconsin
Leukemia, Myelodysplastic Syndromes
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00104806
- Testing
- cholecalciferol, arsenic trioxide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Bone Cancer, Brain Cancer
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
This is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing >10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants…
- Conditions
- Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer
- Trial name
- EARN (NCT06582849)
- Testing
- Standard assistance, Enhanced assistance
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.